Oncotarget: Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
(Impact Journals LLC) Support recently reported findings of clinical benefit when relacorilant is added to paclitaxel-containing therapy in patients with ovarian and pancreatic cancers and provide a new rationale for combining relacorilant with additional cytotoxic agents. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news
Researchers engineer cells to destroy malignant tumor cells but leave the rest alone
(McMaster University) Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news
NYUAD study finds protein aggregation inhibitor can be used to develop cancer therapies
(New York University) A new study provides important insights into the p53 protein, a critical tumor suppressor often mutated and deactivated in cancer, and a key target in the development of cancer therapeutics. Using protein mimetics (small molecules that mimic proteins) originally designed to prevent aggregation of proteins associated with Alzheimer's disease and type II diabetes, the researchers were able to breakdown p53 aggregates and reactivate the protein, leading to the death of cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2021 Category: Cancer & Oncology Source Type: news
An educational intervention can help vapers use their e-cigarettes to quit smoking
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in The Lancet Public Health, they report results from a first-of-its kind nationwide study evaluating a targeted intervention aimed at transforming dual users' e-cigarettes from a product that might maintain smoking into a tool that can be used to aid smoking cessation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news
Bigger may not always be better: Density governs receptor activation on immune cells
(University of Southampton) Scientists have gained novel insights into how an important class of immune receptors called tumour necrosis factor receptors (TNFR) are activated. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news
Application of postbiotics science and technology
(Bentham Science Publishers) The scientific literature confirms that a large part of the molecular mechanism of probiotics is related to their derived postbiotics. These biomolecules, due to their unique pharmacokinetic properties, could be used, in their pure form and with high performance in veterinary, medical, and food practice to improve animal growth rate and health status, prevent and/or treat some acute/chronic diseases, and develop functional foods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news
Hard-working enzyme keeps immune cells in line
(La Jolla Institute for Immunology) Researchers at La Jolla Institute for Immunology (LJI) have shed light on a process in immune cells that may explain why some people develop cardiovascular diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news
Controversies and consensus in thyroid cancer care
(Mary Ann Liebert, Inc./Genetic Engineering News) The American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging released a joint statement on three key topics addressing controversies in thyroid cancer care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2021 Category: Cancer & Oncology Source Type: news
Genetic study of liver cancer reveals new drug target
(PLOS) Drugs targeting the gene MAGEA3 may help block the growth of hepatocellular carcinoma (HCC), the most common type of primary liver cancer and one of the leading causes of cancer deaths in the country. That's one conclusion of a new study analyzing the genetics of HCC tumors published June 24th in the journal PLOS Genetics by Augusto Villanueva of the Icahn School of Medicine at Mount Sinai and colleagues. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
Leopard gecko skin tumors traced to cancer gene
(Howard Hughes Medical Institute) In a rare gecko color variety known as Lemon Frost, scientists have traced an unusual coloring and tendency to form tumors to a gene linked to human melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
Blood test for early detection of cancer: final study results support screening use
(European Society for Medical Oncology) Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher risk of the disease, including patients aged 50 years or older, without symptoms. In a paper published in the leading cancer journal Annals of Oncology, researchers report that the test accurately detected cancer, often before any symptoms arose, while having a very low false positive rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
International study of rare childhood cancer finds genetic clues, potential for tailored therapy
(NIH/National Cancer Institute) In children with rhabdomyosarcoma, or RMS, a rare cancer that affects the muscles and other soft tissues, the presence of mutations in several genes, including TP53, MYOD1, and CDKN2A, appear to be associated with a more aggressive form of the disease and a poorer chance of survival. This finding is from the largest-ever international study on RMS, led by scientists at the National Cancer Institute s (NCI) Center for Cancer Research, part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
Searching for the cell of origin of childhood brain cancer
(Universit à di Trento) Promising findings from a study coordinated by a research team of the University of Trento on medulloblastoma, the most common malignant brain tumor in children affecting the central nervous system. For the first time, scientists have grown organoids in the laboratory to simulate tumor tissue, and have identified the type of cell from which the tumor may originate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
Immunotherapy may be effective for subset of prostate cancer
(Beth Israel Deaconess Medical Center) Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that would allow a substantial number of patients with prostate cancer to benefit from immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
Many cancer patients may need a sequential one-two punch of immunotherapies
(La Jolla Institute for Immunology) New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients do not respond to anti-PD-1 cancer immunotherapies--also called checkpoint inhibitors.The team reports that these patients may have tumors with high numbers of T follicular regulatory (Tfr) cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
